Parenteral Formulation for New Class (DNA Minor Groove Binder) Anti-Infective

点击翻译按钮获取中文摘要

MGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with highpotency against Gram +ve bacteria, including life threatening highly resistant strains such asMRSA. The compound shows unusual physicochemical characteristics which makesolubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oralformulation to treat just a subset of bacterial infections - that of Clostridium difficile. Theformulation for that indication was recently successfully shown to be superior to the goldstandard drug (vancomycin) in the classic Hamster model. To be able to utilise this new classof drug against the most troublesome infectious diseases we need to extend the formulationsin development to be able to successfully produce a reproducible and stable product capableof being given by the intravenous route to patients who are at risk of death due to resistantbacterial and other infections.